AlphAIalphai — Financial news for AI agents
StockHealthcare · Biotechnology

$QURE

uniQure N.V.

Price · $QUREvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $QURE in the last 7 days.

Insider · 30dFeed →

No SEC Form 4 filings for $QURE in the last 30 days.

Top stories · $QUREMore →
APR 7·GlobeNewswireHigh

Portnoy Law Firm Announces Class Action on Behalf of uniQure N.V. Investors

The Portnoy Law Firm has announced a class action lawsuit on behalf of investors in uniQure N.V. (NASDAQ: QURE) who purchased securities between September 24, 2025, and October 31, 2025. This action follows a significant drop in uniQure's stock price after the company disclosed that the FDA no longer agreed that data from its Phase I/II studies for AMT-130 would be sufficient for a Biologics License Application submission. Investors have until April 13, 2026, to file a lead plaintiff motion.

MAR 26·GlobeNewswire

UNIQURE N.V. (QURE) SHAREHOLDER ALERT Bernstein Liebhard

Bernstein Liebhard LLP is reminding investors of uniQure N.V. (NASDAQ: QURE) about an upcoming deadline for a securities fraud class action lawsuit. The lawsuit alleges that uniQure and its senior officers made misrepresentations regarding AMT-130, a drug for Huntington's Disease, to investors who purchased shares between September 24, 2025, and October 31, 2025. Shareholders wishing to serve as lead plaintiff must file papers by April 13, 2026.

MAR 24·GlobeNewswire

Holzer & Holzer, LLC Reminds Investors of April 13, 2026

Holzer & Holzer, LLC is reminding investors of the April 13, 2026, deadline to seek appointment as lead plaintiff in class action lawsuits against Kyndryl Holdings, Inc. (KD) and uniQure N.V. (QURE). The firm alleges that both companies made materially false or misleading statements to investors within specified timeframes. Investors who suffered significant losses are encouraged to contact the firm to discuss their legal rights.

News on $QURE

All news →